publication . Article . 2017

MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015

Pyoeng Gyun Choe; Ranawaka A.P.M. Perera; Wan Beom Park; Kyoung-Ho Song; Ji Hwan Bang; Eu Suk Kim; Hong Bin Kim; Long Wei Ronald Ko; Sang Won Park; Nam Joong Kim; ...
Open Access
  • Published: 01 Jul 2017 Journal: Emerging Infectious Diseases, volume 23, issue 7, pages 1,079-1,084 (issn: 1080-6040, eissn: 1080-6059, Copyright policy)
  • Publisher: Centers for Disease Control and Prevention (CDC)
We investigated the kinetics of the Middle East respiratory syndrome coronavirus (MERS-CoV) neutralizing and spike protein antibody titers over the course of 1 year in 11 patients who were confirmed by reverse transcription PCR to have been infected during the outbreak in South Korea in 2015. Robust antibody responses were detected in all survivors who had severe disease; responses remained detectable, albeit with some waning, for <1 year. The duration of viral RNA detection (but not viral load) in sputum significantly correlated with the antibody response magnitude. The MERS S1 ELISA antibody titers correlated well with the neutralizing antibody response. Antib...
Persistent Identifiers
free text keywords: Research, MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015, Middle East respiratory syndrome coronavirus, MERS, coronavirus, MERS-CoV, antibody, serology, kinetics, human, South Korea, viruses, zoonoses, neutralization, China, Antibody, biology.protein, biology, Virology, Immunology, Serology, Neutralizing antibody, Coronavirus, medicine.disease_cause, medicine, Viral load, Middle East respiratory syndrome coronavirus, Antibody titer, Sputum, medicine.symptom, business.industry, business, lcsh:Medicine, lcsh:R, lcsh:Infectious and parasitic diseases, lcsh:RC109-216
Related Organizations
18 references, page 1 of 2

1. World Health Organization. WHO MERS-CoV global summary and risk assessment. 2016 Dec 5 [cited 2017 Jan 21].

2. Reusken CB, Messadi L, Feyisa A, Ularamu H, Godeke GJ, Danmarwa A, et al.Geographic distribution of MERS coronavirus among dromedary camels, Africa.Emerg Infect Dis. 2014;20:1370–4. 10.3201/eid2008.140590 25062254 [OpenAIRE] [PubMed] [DOI]

3. Saqib M, Sieberg A, Hussain MH, Mansoor MK, Zohaib A, Lattwein E, et al.Serologic evidence for MERS-CoV infection in dromedary camels, Punjab, Pakistan, 2012–2015.Emerg Infect Dis. 2017;23:550–1. 10.3201/eid2303.161285 28221127 [OpenAIRE] [PubMed] [DOI]

4. Korea Centers for Disease Control and Prevention. Middle East respiratory syndrome coronavirus outbreak in the Republic of Korea, 2015.Osong Public Health Res Perspect. 2015;6:269–78. 10.1016/j.phrp.2015.08.006 26473095 [OpenAIRE] [PubMed] [DOI]

5. Oh MD, Park WB, Choe PG, Choi SJ, Kim JI, Chae J, et al.Viral load kinetics of MERS coronavirus infection.N Engl J Med. 2016;375:1303–5. 10.1056/NEJMc1511695 27682053 [PubMed] [DOI]

6. Kim ES, Choe PG, Park WB, Oh HS, Kim EJ, Nam EY, et al.Clinica l progression and cytokine profiles of Middle East respiratory syndrome coronavirus infection.J Korean Med Sci. 2016;31:1717–25. 10.3346/jkms.2016.31.11.1717 27709848 [OpenAIRE] [PubMed] [DOI]

7. Park WB, Perera RA, Choe PG, Lau EH, Choi SJ, Chun JY, et al.Kinetics of serologic responses to MERS coronavirus infection in humans, South Korea.Emerg Infect Dis. 2015;21:2186–9. 10.3201/eid2112.151421 26583829 [OpenAIRE] [PubMed] [DOI]

8. Corman VM, Albarrak AM, Omrani AS, Albarrak MM, Farah ME, Almasri M, et al.Viral shedding and antibod y response in 37 patients with Middle East respiratory syndrome coronavirus infection.Clin Infect Dis. 2016;62:477–83. 26565003 [OpenAIRE] [PubMed]

9. Perera RA, Wang P, Gomaa MR, El-Shesheny R, Kandeil A, Bagato O, et al.Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013.Euro Surveill. 2013;18:20574. 10.2807/1560-7917.ES2013.18.36.20574 24079378 [PubMed] [DOI]

10. Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, et al.Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia.Emerg Infect Dis. 2016;22:1554–61. 10.3201/eid2209.151164 27532807 [OpenAIRE] [PubMed] [DOI]

11. Payne DC, Iblan I, Rha B, Alqasrawi S, Haddadin A, Al Nsour M, et al.Persistence of antibodies against Middle East respiratory syndrome coronavirus.Emerg Infect Dis. 2016;22:1824–6. 10.3201/eid2210.160706 27332149 [OpenAIRE] [PubMed] [DOI]

12. Alshukairi AN, Khalid I, Ahmed WA, Dada AM, Bayumi DT, Malic LS, et al.Antibody response and disease severity in healthcare worker MERS survivors.Emerg Infect Dis. 2016;22:1113–5. 10.3201/eid2206.160010 27192543 [OpenAIRE] [PubMed] [DOI]

13. Cao WC, Liu W, Zhang PH, Zhang F, Richardus JH. Disappearance of antibodies to SARS-associated coronavirus after recovery.N Engl J Med. 2007;357:1162–3. 10.1056/NEJMc070348 17855683 [PubMed] [DOI]

14. Callow KA, Parry HF, Sergeant M, Tyrrell DA. The time course of the immune response to experimental coronavirus infection of man.Epidemiol Infect. 1990;105:435–46. 10.1017/S0950268800048019 2170159 [OpenAIRE] [PubMed] [DOI]

15. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al.; Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis.J Infect Dis. 2015;211:80–90. 10.1093/infdis/jiu396 25030060 [OpenAIRE] [PubMed] [DOI]

18 references, page 1 of 2
Any information missing or wrong?Report an Issue